TG Therapeutics presented new data at the American Academy of Neurology 2025 annual meeting, including results from the retrospective ENAMOR survey. This survey, encompassing approximately 400 individuals across 21 MS centers, demonstrated a favorable tolerability profile for BRIUMVI in a real-world setting.
The survey observed a lower rate of infusion-related reactions at the first BRIUMVI dose compared to what was seen in Phase 3 trials, potentially attributed to the use of acetaminophen as a pre-medication in real-world practice. This finding suggests practical strategies to enhance patient experience.
Additionally, five-year data on BRIUMVI treatment were presented, showing that the frequency of serious infections remained consistent with the ULTIMATE Phase 3 trials. Importantly, no cases of Progressive Multifocal Leukoencephalopathy (PML) were observed during this extended treatment period, reinforcing the long-term safety profile of BRIUMVI.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.